NGSオンコロジーの世界市場レポート 2025年

NGSオンコロジー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.4％で298億6,000万米ドルに成長します。予測期間における成長の原動力は、コンパニオン診断薬の拡大、がん罹患率の上昇、政府・ヘルスケア投資の増加、幅広い臨床応用、標的治療への関心の高まりです。この期間に予想される主な動向には、AIと機械学習の統合、シングルセルシーケンスの進展、シーケンスプラットフォームの改善、リキッドバイオプシー技術の進歩、ハイスループットシーケンスプラットフォームの開発などがあります。

がんの有病率の増加は、今後数年間のNGSオンコロジー市場の成長を促進すると予想されます。がんは、異常な細胞が制御不能に増殖し、身体の他の部分に広がり、正常な身体機能を破壊する状態です。がんの有病率の上昇は、主に人口の高齢化によるものであり、がんを発症するリスクは年齢とともに増加します。NGSオンコロジーは、腫瘍の詳細な遺伝子プロファイリングを通じて、早期発見、正確な診断、個別化治療を可能にすることで、増大するがん負担に対処する一助となります。米国を拠点とする非営利団体である米国がん協会によると、2022年には世界で約2,000万人のがん患者が新たに報告され、970万人が死亡しています。主に人口増加に牽引され、2050年までに世界のがん患者数は3,500万人に増加すると予想されています。このように、がんの有病率の増加は、NGSオンコロジー市場の拡大を大きく促進します。

NGSオンコロジー市場で事業を展開する企業は、リキッドバイオプシー研究アッセイなど、循環腫瘍DNAの分析を通じて非侵襲的でリアルタイムのがん検出とモニタリングを可能にする革新的ソリューションの開発に注力しています。リキッドバイオプシー研究アッセイとは、血液などの生体液を分析し、がんに関連する遺伝子変異や分子マーカーを検出する診断検査であり、非侵襲的な検出やモニタリングを可能にします。例えば、2024年8月、NGS技術を専門とする米国のバイオテクノロジー企業であるイルミナ社は、NovaSeq Xシリーズユーザー向けに腫瘍学ポートフォリオを拡充しました。同社は、新たに検証されたハイスループットTruSight Oncology 500（TSO 500 HT）とアップデートされたTruSight Oncology 500 ctDNA v2（TSO 500 ctDNA v2）リキッドバイオプシー調査アッセイを発表しました。これらの先進的なアッセイにより、研究室は組織およびリキッドバイオプシーサンプルの両方で腫瘍学研究能力を拡大することができ、シーケンス効率の向上、ランタイムの短縮、NovaSeq Xシリーズで初めて大容量のサンプルを処理できるようになりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のNGSオンコロジーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のNGSオンコロジー市場：成長率分析
• 世界のNGSオンコロジー市場の実績：規模と成長, 2019-2024
• 世界のNGSオンコロジー市場の予測：規模と成長, 2024-2029, 2034F
• 世界のNGSオンコロジー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のNGSオンコロジー市場：シーケンシング技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ターゲットシーケンシング
• ゲノミクス
• トランスクリプトミクス
• エピゲノミクス
• 世界のNGSオンコロジー市場：提供別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラットフォーム
• キット
• サービス
• 世界のNGSオンコロジー市場：ワークフロー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレシーケンシング
• シーケンシング
• データ分析
• 世界のNGSオンコロジー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子スクリーニング
• 遺伝性遺伝子検査
• 造血悪性腫瘍
• 固形腫瘍
• その他
• 世界のNGSオンコロジー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 臨床研究機関（CRO）
• 学術研究機関
• 製薬・バイオテクノロジー企業
• その他
• 世界のNGSオンコロジー市場、ターゲットシーケンシングの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全エクソームシーケンシング（WES）
• アンプリコンベースシーケンシング
• ハイブリダイゼーションベースシーケンシング
• 世界のNGSオンコロジー市場：ゲノミクスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全ゲノムシーケンシング（WGS）
• 構造変異検出
• コピー数多型（CNV）解析
• 世界のNGSオンコロジー市場：トランスクリプトミクスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• RNAシーケンシング
• シングルセルトランスクリプトミクス
• ノンコーディングRNA解析
• 世界のNGSオンコロジー市場：エピゲノミクスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAメチル化シーケンシング
• クロマチン免疫沈降シーケンシング
• ヒストン修飾解析

第7章 地域別・国別分析

• 世界のNGSオンコロジー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のNGSオンコロジー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• NGSオンコロジー市場：競合情勢
• NGSオンコロジー市場：企業プロファイル
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Qiagen N.V.
• Tecan Trading AG
• Myriad Genetics
• Takara Bio Inc.
• Beijing Genomics Institute（BGI）
• Caris Life Sciences
• Foundation Medicine
• Paradigm Diagnostics
• Pacific Bioscience
• Horizon Discovery Group plc
• Creative-Biolabs
• Xcelris Labs Ltd.
• Partek Inc.
• 4baseCare
• SciGenom Labs Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• NGSオンコロジー市場2029：新たな機会を提供する国
• NGSオンコロジー市場2029：新たな機会を提供するセグメント
• NGSオンコロジー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Next-generation sequencing (NGS) oncology involves the use of advanced sequencing technologies to examine the genetic composition of cancer cells. It helps identify specific mutations, genetic alterations, and biomarkers that can guide personalized treatment plans, predict responses to therapies, and enhance overall cancer management. NGS oncology facilitates precision medicine, where treatments are tailored to the genetic profile of the tumor.

The primary sequencing technologies in NGS oncology include targeted sequencing, genomics, transcriptomics, and epigenomics. Targeted sequencing is a genomic method that focuses on sequencing specific genes or regions within the genome to detect genetic variations linked to diseases or traits. These technologies are available in platforms, kits, and services. The workflow includes stages such as pre-sequencing, sequencing, and data analysis. They are applied in various areas, including genetic screening, hereditary genetic testing, hematological malignancies, solid tumors, and more. Key end users include hospitals and clinics, clinical research organizations (CROs), academic and research institutions, pharmaceutical and biotechnology companies, and others.

The NGS oncology market research report is one of a series of new reports from The Business Research Company that provides NGS oncology market statistics, including the NGS oncology industry global market size, regional shares, competitors with the NGS oncology market share, detailed NGS oncology market segments, market trends, and opportunities, and any further data you may need to thrive in the NGS oncology industry. This NGS oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The NGS oncology market size has grown rapidly in recent years. It will grow from $17.36 billion in 2024 to $19.39 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth during the historic period can be attributed to the increasing incidence of cancer, expanding research in cancer genomics, rising public awareness, development of healthcare infrastructure, and growing demand for personalized medicine.

The NGS oncology market size is expected to see rapid growth in the next few years. It will grow to $29.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The projected growth in the forecast period is driven by the expansion of companion diagnostics, rising cancer prevalence, increased government and healthcare investments, broader clinical applications, and growing interest in targeted therapies. Key trends expected in this period include the integration of AI and machine learning, progress in single-cell sequencing, improvements in sequencing platforms, advancements in liquid biopsy technology, and developments in high-throughput sequencing platforms.

The increasing prevalence of cancer is expected to drive the growth of the NGS oncology market in the coming years. Cancer is a condition where abnormal cells grow uncontrollably and spread to other parts of the body, disrupting normal bodily functions. The rising prevalence of cancer is primarily due to aging populations, as the risk of developing cancer increases with age. NGS oncology helps address this growing cancer burden by enabling early detection, accurate diagnosis, and personalized treatment through detailed genetic profiling of tumors. According to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, around 20 million new cancer cases were reported globally, resulting in 9.7 million deaths. Driven mainly by population growth, the global cancer burden is expected to rise to 35 million cases by 2050. Thus, the increasing prevalence of cancer will significantly drive the expansion of the NGS oncology market.

Companies operating in the NGS oncology market are focusing on developing innovative solutions, such as liquid biopsy research assays, to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids such as blood to detect genetic mutations or molecular markers linked to cancer, allowing for non-invasive detection and monitoring. For example, in August 2024, Illumina Inc., a U.S.-based biotechnology company specializing in NGS technology, expanded its oncology portfolio for NovaSeq X Series users. The company introduced the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assays. These advanced assays enable laboratories to expand their oncology research capabilities for both tissue and liquid biopsy samples, offering improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.

In December 2024, Deerfield Management Company, a U.S.-based investment firm, acquired Singular Genomics for an undisclosed amount. This acquisition aims to strengthen Deerfield's portfolio by integrating Singular Genomics' next-generation sequencing and spatial multiomics technologies, advancing research and clinical applications. Singular Genomics is a U.S.-based biotechnology company specializing in NGS and multiomics technologies.

Major players in the NGS oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, and SciGenom Labs Pvt. Ltd.

North America was the largest region in the NGS oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS oncology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the NGS oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The NGS oncology market consists of revenues earned by entities by providing services such as companion diagnostics, liquid biopsy analysis, genetic mutation analysis, bioinformatics, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The NGS oncology market also includes sales of target enrichment kits, library preparation kits, data analysis pipelines, bioinformatics software, and tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

NGS Oncology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ngs oncology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ngs oncology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ngs oncology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Sequencing Technology: Targeted Sequencing; Genomics; Transcriptomics; Epigenomics
• 2) By Offering: Platform; Kits; Services
• 3) By Workflow: Pre-Sequencing; Sequencing; Data Analysis
• 4) By Application: Genetic Screening; Hereditary Genetic Testing; Hematological Malignancies; Solid Tumors; Other Applications
• 5) By End User: Hospitals And Clinics; Clinical Research Organizations (CROs); Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
• Subsegments:
• 1) By Targeted Sequencing: Whole Exome Sequencing (WES); Amplicon-Based Sequencing; Hybridization-Based Sequencing
• 2) By Genomics: Whole Genome Sequencing (WGS); Structural Variant Detection; Copy Number Variation (CNV) Analysis
• 3) By Transcriptomics: RNA Sequencing; Single-Cell Transcriptomics; Non-coding RNA Analysis
• 4) By Epigenomics: DNA Methylation Sequencing; Chromatin Immunoprecipitation Sequencing; Histone Modification Analysis
• Companies Mentioned: Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Eurofins Scientific SE; Illumina Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. NGS Oncology Market Characteristics

3. NGS Oncology Market Trends And Strategies

4. NGS Oncology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global NGS Oncology Growth Analysis And Strategic Analysis Framework

• 5.1. Global NGS Oncology PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global NGS Oncology Market Growth Rate Analysis
• 5.4. Global NGS Oncology Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global NGS Oncology Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global NGS Oncology Total Addressable Market (TAM)

6. NGS Oncology Market Segmentation

• 6.1. Global NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Sequencing
• Genomics
• Transcriptomics
• Epigenomics
• 6.2. Global NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platform
• Kits
• Services
• 6.3. Global NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Sequencing
• Sequencing
• Data Analysis
• 6.4. Global NGS Oncology Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Screening
• Hereditary Genetic Testing
• Hematological Malignancies
• Solid Tumors
• Other Applications
• 6.5. Global NGS Oncology Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Clinical Research Organizations (CROs)
• Academic And Research Institutes
• Pharmaceutical And Biotechnology Companies
• Other End Users
• 6.6. Global NGS Oncology Market, Sub-Segmentation Of Targeted Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Exome Sequencing (WES)
• Amplicon-Based Sequencing
• Hybridization-Based Sequencing
• 6.7. Global NGS Oncology Market, Sub-Segmentation Of Genomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Genome Sequencing (WGS)
• Structural Variant Detection
• Copy Number Variation (CNV) Analysis
• 6.8. Global NGS Oncology Market, Sub-Segmentation Of Transcriptomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA Sequencing
• Single-Cell Transcriptomics
• Non-coding RNA Analysis
• 6.9. Global NGS Oncology Market, Sub-Segmentation Of Epigenomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Methylation Sequencing
• Chromatin Immunoprecipitation Sequencing
• Histone Modification Analysis

7. NGS Oncology Market Regional And Country Analysis

• 7.1. Global NGS Oncology Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global NGS Oncology Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific NGS Oncology Market

• 8.1. Asia-Pacific NGS Oncology Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China NGS Oncology Market

• 9.1. China NGS Oncology Market Overview
• 9.2. China NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India NGS Oncology Market

• 10.1. India NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan NGS Oncology Market

• 11.1. Japan NGS Oncology Market Overview
• 11.2. Japan NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia NGS Oncology Market

• 12.1. Australia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia NGS Oncology Market

• 13.1. Indonesia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea NGS Oncology Market

• 14.1. South Korea NGS Oncology Market Overview
• 14.2. South Korea NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe NGS Oncology Market

• 15.1. Western Europe NGS Oncology Market Overview
• 15.2. Western Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK NGS Oncology Market

• 16.1. UK NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany NGS Oncology Market

• 17.1. Germany NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France NGS Oncology Market

• 18.1. France NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy NGS Oncology Market

• 19.1. Italy NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain NGS Oncology Market

• 20.1. Spain NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe NGS Oncology Market

• 21.1. Eastern Europe NGS Oncology Market Overview
• 21.2. Eastern Europe NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia NGS Oncology Market

• 22.1. Russia NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America NGS Oncology Market

• 23.1. North America NGS Oncology Market Overview
• 23.2. North America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA NGS Oncology Market

• 24.1. USA NGS Oncology Market Overview
• 24.2. USA NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada NGS Oncology Market

• 25.1. Canada NGS Oncology Market Overview
• 25.2. Canada NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America NGS Oncology Market

• 26.1. South America NGS Oncology Market Overview
• 26.2. South America NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil NGS Oncology Market

• 27.1. Brazil NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East NGS Oncology Market

• 28.1. Middle East NGS Oncology Market Overview
• 28.2. Middle East NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa NGS Oncology Market

• 29.1. Africa NGS Oncology Market Overview
• 29.2. Africa NGS Oncology Market, Segmentation By Sequencing Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa NGS Oncology Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa NGS Oncology Market, Segmentation By Workflow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. NGS Oncology Market Competitive Landscape And Company Profiles

• 30.1. NGS Oncology Market Competitive Landscape
• 30.2. NGS Oncology Market Company Profiles
  • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. NGS Oncology Market Other Major And Innovative Companies

• 31.1. Qiagen N.V.
• 31.2. Tecan Trading AG
• 31.3. Myriad Genetics
• 31.4. Takara Bio Inc.
• 31.5. Beijing Genomics Institute (BGI)
• 31.6. Caris Life Sciences
• 31.7. Foundation Medicine
• 31.8. Paradigm Diagnostics
• 31.9. Pacific Bioscience
• 31.10. Horizon Discovery Group plc
• 31.11. Creative-Biolabs
• 31.12. Xcelris Labs Ltd.
• 31.13. Partek Inc.
• 31.14. 4baseCare
• 31.15. SciGenom Labs Pvt. Ltd.

32. Global NGS Oncology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The NGS Oncology Market

34. Recent Developments In The NGS Oncology Market

35. NGS Oncology Market High Potential Countries, Segments and Strategies

• 35.1 NGS Oncology Market In 2029 - Countries Offering Most New Opportunities
• 35.2 NGS Oncology Market In 2029 - Segments Offering Most New Opportunities
• 35.3 NGS Oncology Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer